Publication at First Faculty of Medicine |
2019
Abstract
Multiple sclerosis is a chronic autoimmune disease of the central nervous system that is characterized by inflammatory processes that can lead to demyelination and loss of axons and neurons, which is major cause of permanent disability. Multiple sclerosis usually begins around the age between 20 and 40 years and disease course is typically relapsing-remitting.
Disease modifying drugs are a group of treatments for people with relapsing MS that reduce the disease activity and can delay an onset of the secondary progressive phase. We weigh benefits against risks of each kind of drug for each individual patient before we consider prescribing disease modifying drugs